261 results about "Glycopeptide" patented technology

The invention discloses preparation and application of antioxidative, anti-inflammatory and hypoglycemic lactoferrin peptide, and belongs to the field of food science and nutriology. According to the invention, lactoferrin is used as a raw material, hydrolysis is carried out by using a composite enzymatic hydrolysis method, and the molecular weight is obtained by ultrafiltration; the preparation method comprises the following steps: preparing a component of antioxidant, anti-inflammatory and hypoglycemic peptide from the active peptide YLSW (Tyr-Leu-Ser-Trp), carrying out freeze drying on the component to obtain peptide powder rich in antioxidant, anti-inflammatory and hypoglycemic peptides, identifying peptide fragments contained in the peptide powder by utilizing an LC-MS / MS technology, and screening out the active peptide YLSW (Tyr-Leu-Ser-Trp) with antioxidant, anti-inflammatory and hypoglycemic triple functions. The active peptide is added into the product to obtain the antioxidant, anti-inflammatory and hypoglycemic functional product.

The invention relates to the technical field of biology, in particular to glycopeptide antibiotic and application thereof. According to the invention, a biosynthetic gene cluster for synthesizing a brand new glycopeptide antibiotic skeleton is excavated, and brand new glycopeptide antibiotics Varsomycin A, B and C with novel chemical structures are obtained through heterologous expression; the traditional Chinese medicine composition has a remarkable antibacterial effect on clinically drug-resistant strains. Important fermentation strains and precursor compound molecules are provided for research and development of new drugs of glycopeptide antibiotics, and important application prospects and economic values are achieved.

The invention relates to the technical field of bioanalytical chemistry, in particular to a method for simultaneously enriching and separating glycopeptides and phosphopeptides by using a bionic hydrophilic adsorbent, which specifically comprises the following steps: step 1, preparing a polyether-ether-ketone (PEEK) framework by using a fused deposition modeling method (FDM); 2, soaking the obtained PEEK framework in an aqueous solution containing dopamine hydrochloride and tris (hydroxymethyl) aminomethane, and carrying out a reaction; step 3, then, adding a mixed solution containing hyaluronic acid methacrylate, vinyl phosphoric acid, N, N-dimethyl bisacrylamide and phenyl-2, 4, 6-trimethylbenzoyl lithium phosphate into the PEEK framework; in the invention, in the aspect of material preparation, a fused deposition modeling method (FDM) is adopted to prepare a polyether-ether-ketone (PEEK) frame, and the material has good mechanical properties and chemical stability and can bear a series of subsequent complex treatment processes without being damaged.

The invention discloses cubilose sialic acid glycan peptide capable of improving lung inflammation and application of the cubilose sialic acid glycan peptide. The ratio of fucose modified sugar chains in the cubilose sialic acid glycan peptide is 30-60%, the ratio of sialic acid modified sugar chains in the cubilose sialic acid glycan peptide is 20-40%, the core structure of the fucose type is (HexNAc) 3 (Man) 3 (Fuc) 1, the core structure of the sialic acid type is (HexNAc) 3 (Man) 3 (Gal) 1 (Fuc) 1 (NeuAc) 1, the neutral sugar dissolution rate of the cubilose sialic acid glycan peptide is high, and the glycopeptide shown in SEQ ID NO 2 has a good inflammation improving effect.

The invention discloses a 3D printing PCL / nHA combined bionic glycopeptide hydrogel scaffold for infected bone defect substitution and a preparation method thereof, and belongs to the field of biomedical materials. The scaffold comprises a 3D printed PCL / nHA porous scaffold, the 3D printed PCL / nHA porous scaffold is provided with three-dimensional interconnected micro-channels, the mass percentage of nHA is 10-30wt%, the scaffold is further filled with a bionic glycopeptide hydrogel layer formed by mixing methylacryloylated gelatin, aldehyde bletilla striata polysaccharide, antibacterial peptide and a photoinitiator according to the ratio of 10: 4: 2: 1 and carrying out ultraviolet irradiation polymerization, phenyl lithium phosphate is adopted as the photoinitiator, and the bionic glycopeptide hydrogel layer is a bionic glycopeptide hydrogel layer. And 3D printing process parameters are accurately controlled. The preparation method comprises the steps of PCL / nHA porous scaffold preparation, pretreatment, finished product treatment, bionic glycopeptide hydrogel solution preparation, filling polymerization and the like. The scaffold disclosed by the invention integrates excellent mechanical properties, biocompatibility, antibacterial and anti-inflammatory capabilities and strong bone induction biological activity, provides an ideal material for repairing infected bone defects, and effectively overcomes many defects of a traditional skull repairing material.

The present invention provides a melittin glycopeptide and a preparation method and use thereof, belonging to the field of polypeptide drugs. The melittin glycopeptide described in the present invention has Ac‑GIGAVLKVLTTGLPALISWIKRKRQQ‑NH2 as a peptide chain, and the arginine at the 22nd and / or 24th positions is glycosylated. The present invention successfully prepares a class of melittin glycopeptides, and proves that the hemolytic effect of this class of melittin glycopeptides is greatly reduced compared to melittin, effectively solving the problem of strong hemolysis of melittin in the prior art, which is beneficial to clinical application. At the same time, the antibacterial activity and tumor cell inhibition activity of some melittin glycopeptides prepared by the present invention are significantly better than those of melittin, and have good application prospects in the research and development of preparation of antibacterial drugs and anti-tumor drugs.

The preparation method comprises the following steps: by taking natural chitosan, epsilon-polylysine and polyphenol as raw materials, firstly, respectively preparing polyphenol modified chitosan and carboxyphenylboronic acid modified polylysine through a carbodiimide coupling method, then, mixing single-component solutions of the polyphenol modified chitosan and the carboxyphenylboronic acid modified polylysine, and then, preparing the antibacterial and antioxidant glycopeptide hydrogel based on the polyphenol. And the antibacterial and antioxidant glycopeptide hydrogel is obtained by virtue of the synergistic effect of the phenolic hydroxyl group-boric acid group dynamic bond and the amino group-carboxyl group. The hydrogel disclosed by the invention has broad-spectrum antibacterial property and glucose response oxidation resistance, has self-healing capability and strong wound adhesion, is excellent in biocompatibility and can be naturally degraded; and the process is simple, convenient and controllable, large-scale production is easy to realize, the hydrogel can be used as a wound dressing for treating chronic difficult-to-heal wounds such as diabetes mellitus in a targeting manner, and integrated nursing of antibiosis, antioxidation, wound adhesion and self-repairing is realized.

The invention belongs to the field of cell culture, and relates to an MRC-5 cell serum-free medium with definite components and application thereof. Nutrient substances of the serum-free culture medium comprise amino acids, vitamins, inorganic salts, trace elements, proteins, other substances and supplements. According to the MRC-5 cell serum-free culture medium, the concentration of the amino acid, the inorganic salt, the vitamin and the serum substitute is adjusted, and meanwhile, the Chinese yam glycopeptide is added, so that adherent growth of MRC-5 cells can be effectively promoted, and the technical problem that a new variety of MRC-5 cell serum-free culture medium is lacked in the prior art is solved; the requirements of nutrient substances, carbon sources and genetic material nutrient substances required by MRC-5 cell in-vitro culture can be met.

The application relates to a synthesis method of an anti-freezing glycopeptide polypeptide and belongs to the technical field of polypeptide drug synthesis. The method comprises the following steps: 2-CL-Resin is used as a carrier resin, under the condition of adding an activating agent, the carrier resin and alanine are coupled to obtain Fmoc-Ala-2-CL-Resin; according to the amino acid sequence of the anti-freezing glycopeptide, other amino acids are sequentially coupled through a solid-phase synthesis method; after a protecting group is removed and the carrier resin is cleaved, the anti-freezing glycopeptide crude peptide is obtained; and after purification, salt conversion and freeze-drying, the anti-freezing glycopeptide polypeptide is obtained. The method has the advantages of short synthesis period, low cost, easy post-treatment, few by-products, high product yield, facilitation of large-scale production of the anti-freezing glycopeptide, and considerable economic applicative value and wide application prospect.

The application discloses a glucagon peptide-1 and glucagon receptor dual-agonistic polypeptide and application thereof, and the polypeptide structure is shown in the following general formula (I). The dual-agonistic polypeptide has dual-agonistic activity on human GLP-1 and glucagon receptors. The GLP-1 / glucagon receptor dual-agonistic polypeptide can effectively reduce blood sugar and weight, and has obvious lipid-regulating effect. The GLP-1 / glucagon receptor dual-agonistic polypeptide is stable in vivo, and is suitable to be used as an active component of drugs for diabetes, obesity, hyperlipidemia and the like.

The invention discloses a high-throughput complete glycopeptide full-automatic online enrichment and separation analysis method which comprises the following steps: firstly, building a full-automatic online enrichment and separation analysis system capable of realizing synchronization of enrichment and separation analysis through switching of a ten-way valve; the full-automatic on-line enrichment and separation analysis system is adopted to enrich complete glycopeptides in a first-needle sample, then the full-automatic on-line enrichment and separation analysis system is adopted to enrich complete glycopeptides in a next-needle sample and separate and analyze complete glycopeptides in a previous-needle sample at the same time, and the above steps are repeated. The separation analysis of the complete glycopeptide in the last needle of sample is completed; the method has the advantages that the complete glycopeptide can be quickly, fully automatically and online enriched, separated and analyzed, the operation in the enrichment process is completely controllable, the problems of high sample loss rate, poor enrichment repeatability and low liquid chromatography separation degree can be greatly reduced, the time required by the complete glycopeptide enrichment and separation analysis steps is superposed, and the analysis accuracy is greatly improved. And the time required by the whole process can be obviously reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to a cyclic ester peptide compound, a producing strain thereof, a preparation method and application of the cyclic ester peptide compound in preparation of antibacterial medicines. The invention provides a cyclic ester peptide compound as shown in a formula I, a stereoisomer, a tautomer and an isotope derivative of the cyclic ester peptide compound, or a pharmaceutically acceptable salt of the cyclic ester peptide compound, a producing strain Streptomyces alboflavus sp.NX-12 of the cyclic ester peptide compound, and fermentation, separation and purification methods of the cyclic ester peptide compound and the stereoisomer, the tautomer and the isotope derivative of the cyclic ester peptide compound. The cyclic ester peptide compound has strong inhibitory activity on a variety of gram-positive bacteria, can be used for preparing antibacterial drugs, shows application potential in treatment of infection and other related diseases, and compared with the existing similar gram-positive bacterium-resistant glycopeptide antibiotic vancomycin, the cyclic ester peptide compound has the advantages that the cyclic ester peptide compound can be used for preparing the antibacterial drugs; the cyclic ester peptide compound disclosed by the invention has an equivalent antibacterial effect. The preparation method of the cyclic ester peptide compound is simple in process, short in time consumption, capable of greatly reducing the medicine cost and suitable for large-scale production. # imgabs0 #

The present disclosure provides methods, compositions, and kits for the rapid release, labeling, and detection of O-glycans present on a glycoconjugate, such as a glycoprotein, glycopeptide, peptidoglycan, or proteoglycan of interest. The compositions and methods allow the released O-glycans to be subjected to high-throughput analysis.

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting lycium barbarum glycopeptide metabolites in rat plasma and tissues based on non-targeted metabonomics. According to the method, after rat lycium barbarum glycopeptides are administered through intragastric administration, blood, liver, intestine, lung and brain tissue samples after administration are collected. A UPLC-Q-TOF-MS (Ultra Performance Liquid Chromatography-Quadrupole Time of Flight Mass Spectrometry) analysis method is combined with a statistical analysis method comprising principal component analysis (PCA) and orthogonal-partial least squares discriminant analysis (OPLS-DA) to carry out in-vivo metabonomics analysis on the wolfberry glycopeptide. Then, based on a human metabolome database (HMDB), lycium barbarum glycopeptide differential metabolite is searched, so that the pharmacological action mechanism of the lycium barbarum glycopeptide is clarified from the perspective of metabolism, and a foundation is laid for deep research and development of the medicinal value of the lycium barbarum glycopeptide in future.

The invention discloses a stage targeting scallop adductor non-phosphorus water-retaining agent containing antifreeze glycopeptide and application, and relates to the technical field of food additives. The antifreeze glycopeptide-containing stage targeting scallop adductor phosphorus-free water-retaining agent consists of an agent A and an agent B, and does not contain phosphate additives, the agent A is permeable anti-freezing liquid and is prepared from the following components in percentage by mass: 5.0 percent to 9.0 percent of trehalose, 3.0 percent to 5.0 percent of sorbitol, 0.8 percent to 1.5 percent of sodium citrate, 0.4 percent to 1.0 percent of compound amino acid, 0.01 percent to 0.1 percent of high-activity anti-freezing glycopeptide, 0.01 percent to 0.05 percent of vitamin C, 0.01 percent to 0.05 percent of rosemary extract and the balance of water. According to the antifreeze glycopeptide-containing phase-targeting scallop adductor non-phosphorus water-retaining agent and the application thereof, ice crystal damage and protein denaturation are inhibited from the source, and cell-level protection of scallop adductors is realized. Through detection, the unfreezing loss rate of the treated scallop adductor is as low as about 2.12%, the cooking loss rate is as low as about 10.63%, and the water retention capacity is close to that of a commercially available phosphate water retention agent and is remarkably superior to that of an existing non-phosphorus water retention agent.

The invention discloses skipjack glycopeptide with anti-inflammatory activity and a preparation method and application thereof, and belongs to the technical field of deep processing of marine fish food. The technical problem to be solved is to improve the anti-inflammatory effect and the cell proliferation effect. The key point of the technical scheme is as follows: the molecular weight distribution of the skipjack glycopeptide with the anti-inflammatory activity comprises the following components in percentage by mass: 10.8-13.2% of components with the molecular weight smaller than or equal to 300 Da, and 86.8-89.2% of components with the molecular weight ranging from 300 Da to 2000 Da.

The present invention relates to a method for producing cytidine 5′-monophospho-N-acetyl-neuraminic acid (CMP-Neu5Ac, 1) from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, cytidine and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucosamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3). Further, said process may be adapted to produce Neu5Acylated i.e. sialylated biomolecules and biomolecules including a saccharide, a peptide, a protein, a glycopeptide, a glycoprotein, a glycolipid, a glycan, an antibody, and a glycoconjugate, in particular, an antibody drug conjugate, and a carbohydrate conjugate vaccine, or a flavonoid.

A FAP glycopeptide as represented by Formula (I), and a radionuclide marker thereof and the use thereof. The FAP glycopeptide is obtained by modifying a linker portion that forms a cyclic peptide on the basis of a polypeptide FAP-2286 structure, and further introducing mono- or di-saccharide molecules. After being marked with radionuclides, the glycopeptide shows superior tumor uptake and lower liver uptake compared to FAP-2286, resulting in better imaging outcomes, facilitating the development of candidate radionuclide pharmaceuticals with further research value, and contributing to the ultimate goal of developing FAP-targeted cyclic peptide radiopharmaceuticals with independent intellectual property rights. Drawing_references_to_be_translated

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and / or PIVKA-II in the detection of HCC.

The present application relates to the technical field of microbial fermentation, in particular to a polyporus arctorus and a culture method and application thereof. A polyporus arctorus YH-DB-1 is screened in the present application, and a large amount of glycopeptide can be extracted from the mycelium of the strain by culturing the strain, the peptide content in the glycopeptide can reach more than 45%, and the present application solves the problem of low peptide yield in the existing polyporus arctorus glycopeptide.

This invention relates to infant formulae or follow-on formulae suitable for children under the age of 2 years, and their use in the dietary management of phenylketonuria and tyrosinaemia. In particular, the invention relates infant formulae or follow-on formulae comprising casein glycomacropeptide and free amino acids as well as their use in the dietary management of phenylketonuria and tyrosinaemia, and the symptoms thereof. The invention relates to a mixture of free amino acids for use in manufacturing the infant formulae or follow-on formula.

Methods and kits for treating and / or preventing a cardiac disorder are disclosed. The methods can include administering an indole metabolite to a subject. The methods can also include administering a glycopeptide antibiotic to the subject.

The invention relates to a self-adjuvant based on a virus source glycopeptide and an application of the self-adjuvant in preparation of a vaccine, the self-adjuvant is a glycopeptide fragment based on a varicella-zoster virus (VZV) source, and the self-adjuvant is a B cell epitope structural domain V50 glycopeptide (from 50 valine to 135 isoleucine, V50-I135) in glycoprotein E. The invention further relates to a preparation method of the self-adjuvant based on the virus source glycopeptide and application of the self-adjuvant based on the virus source glycopeptide in preparation of the vaccine. The V50 glycopeptide and the novel coronavirus RBD are subjected to fusion expression and then are coupled to the surfaces of the nanoparticles based on ferritin to form the self-adjuvant vaccine, so that the levels of RBD specific antibodies and pseudovirus neutralizing antibodies induced by the RBD nanoparticle vaccine can be remarkably enhanced, and the V50 glycopeptide has a synergistic effect in B cell response and T cell response of systemic systemic immunity and mucosal immunity at the same time. The immune protection effect of the novel coronavirus RBD nanoparticle vaccine is obviously improved.

The present invention relates to a monoclonal antibody reacting with a glycopeptide and use thereof. The present invention provides a monoclonal antibody which is an epitope of both a fucose moiety and an amino acid of a peptide moiety. The antibody of the present invention is a monoclonal antibody reacting with a glycopeptide containing a core fucose and an amino acid of 4 or more residues continuously from an asparagine of an additional sugar chain toward a C-terminal side, the antibody being an epitope of both the core fucose of the glycopeptide and an amino acid of the glycopeptide which is 3 or more residues from the asparagine of the additional sugar chain toward the C-terminal side.

The invention belongs to the technical field of deep processing of lycium barbarum, and particularly relates to a lycium barbarum polysaccharide molecular weight grading co-production method and an anti-tumor product. The molecular weight grading co-production method of lycium barbarum polysaccharide comprises the following steps: crushing dried lycium barbarum, carrying out subcritical extraction, collecting extraction residues to obtain lycium barbarum residues, adding water, pulping, and separating to obtain lycium barbarum juice and lycium barbarum seeds. And mixing the lycium barbarum seed washing water with the lycium barbarum juice to obtain the lycium barbarum pulp. Performing enzymolysis on the Chinese wolfberry pulp to obtain Chinese wolfberry pulp enzymatic hydrolysate; and centrifuging the wolfberry pulp enzymatic hydrolysate to obtain the wolfberry pulp. Performing ceramic membrane filtration, 100kDa ultrafiltration, 30kDa ultrafiltration, 10kDa ultrafiltration and 3kDa ultrafiltration on the Chinese wolfberry pulp, and respectively collecting filtrate and interception liquid to obtain Chinese wolfberry polysaccharide and Chinese wolfberry glycopeptide. And fermenting the 3KDa ultrafiltrate to obtain the Chinese wolfberry wine and the Chinese wolfberry brandy. According to the method, the lycium barbarum polysaccharide separation efficiency is high, the process synergy is high, and a new thought is provided for development of the lycium barbarum industry.

The invention relates to the technical field of biology, in particular to pigeon egg white glycopeptide and a preparation method and application thereof. The amino acid sequence of the pigeon egg white glycopeptide disclosed by the invention is KVLHFDNVTEVGDA, and N glycosylation modification exists. The pigeon egg white glycopeptide prepared by the invention has obvious capacity of inhibiting the proliferation of colon cancer cells, has potential anti-tumor activity, and can reduce the migration capacity of colon cancer cells under the condition of low dosage of pigeon egg white glycopeptide. According to the pigeon egg white glycopeptide, the preparation process is simple, the added value of pigeon eggs is improved, deep research of pigeon egg white protein and small-molecule glycopeptide is facilitated, and the pigeon egg white glycopeptide has important significance on product development of the pigeon eggs.

The invention provides a method for preparing micromolecular glucosamine peptide by utilizing leftover materials of aquatic products. The method comprises the following three steps: firstly, treating raw materials through alkaline hydrolysis, and removing impurities; secondly, chitinase, deacetylase and collagenase are added at a certain temperature for enzymolysis, and the raw materials are converted into micromolecular collagen peptide; and finally, carrying out activated carbon adsorption, ultrafiltration membrane filtration and heating evaporation concentration to obtain a high-purity glucosamine peptide solution. The method is efficient, environment-friendly and low in cost, waste generated in the aquatic product processing process can be fully utilized and converted into micromolecular amino glycopeptides with commercial value, cyclic utilization of resources is promoted, and the method has high sustainable development significance and wide industrial application prospects.

The invention belongs to the technical field of biological medicine, and discloses ovomucoprotein glycopeptide and application thereof. According to the application of the ovomucoprotein glycopeptide in preparing the medicine for preventing or treating the alcohol-induced acute gastric mucosal lesion, the percentage of the gastric mucosal lesion area can be reduced to 1.0% or below when the ovomucoprotein glycopeptide is used for protection. The invention creatively discovers and verifies that the glycopeptide derived from ovomucin has a remarkable protective effect on acute gastric mucosal lesion induced by alcohol. According to the discovery of the application, the application field of the natural active ingredient ovomucin is definitely expanded to the protection of acute gastric mucosal lesion for the first time, the technical problem that efficient and natural gastric mucosal protection ingredients are lacked in the prior art is solved, and a brand-new material basis and a clear direction are provided for developing a novel gastric mucosal protective agent.

The invention discloses a nereis glycopeptide SC2-3 as well as a preparation method and application thereof, and the preparation method comprises the following steps: firstly extracting crude polysaccharide from nereis, and then identifying by means of column chromatography purification, spectroscopy and the like to obtain the nereis glycopeptide SC2-3 with the relative molecular mass of 5061Da. The glycopeptide SC2-3 is obtained by taking nereis as a raw material, and pharmacological experiments show that the nereis glycopeptide SC2-3 has immunomodulatory activity, can improve low mouse immunologic function induced by cyclophosphamide chemotherapeutic drugs, and is expected to be developed into an immunologic adjuvant for assisting in resisting tumors.